CY1109985T1 - Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων - Google Patents
Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτωνInfo
- Publication number
- CY1109985T1 CY1109985T1 CY20101100375T CY101100375T CY1109985T1 CY 1109985 T1 CY1109985 T1 CY 1109985T1 CY 20101100375 T CY20101100375 T CY 20101100375T CY 101100375 T CY101100375 T CY 101100375T CY 1109985 T1 CY1109985 T1 CY 1109985T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- protestous
- suspensions
- compositions
- proteasome activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Η παρούσα εφεύρεση παρέχει ενώσεις βορονικού οξέος, βορονικούς εστέρες και συνθέσεις αυτών που μπορούν να διαμορφώνουν την απόπτωση, όπως με αναστολή της δραστηριότητας πρωτεασώματος. Οι ενώσεις και οι συνθέσεις μπορούν να χρησιμοποιηθούν σε μεθόδους επαγωγής απόπτωσης και στη θεραπεία νόσων όπως είναι ο καρκίνος και άλλες διαταραχές που σχετίζονται άμεσα ή έμμεσα με τη δραστηριότητα πρωτεασώματος.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65237005P | 2005-02-11 | 2005-02-11 | |
US11/351,193 US7468383B2 (en) | 2005-02-11 | 2006-02-09 | Proteasome inhibitors and methods of using the same |
EP06734698A EP1846424B1 (en) | 2005-02-11 | 2006-02-10 | Proteasome inhibitors and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109985T1 true CY1109985T1 (el) | 2014-09-10 |
Family
ID=36579482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100375T CY1109985T1 (el) | 2005-02-11 | 2010-04-27 | Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων |
Country Status (20)
Country | Link |
---|---|
US (2) | US7468383B2 (el) |
EP (1) | EP1846424B1 (el) |
JP (1) | JP2008530108A (el) |
AT (1) | ATE456571T1 (el) |
AU (1) | AU2006213814B2 (el) |
CA (1) | CA2597273C (el) |
CY (1) | CY1109985T1 (el) |
DE (1) | DE602006012013D1 (el) |
DK (1) | DK1846424T3 (el) |
ES (1) | ES2339698T3 (el) |
HK (1) | HK1106534A1 (el) |
IL (1) | IL184678A (el) |
MX (1) | MX2007009664A (el) |
MY (1) | MY147921A (el) |
NZ (1) | NZ560607A (el) |
PL (1) | PL1846424T3 (el) |
PT (1) | PT1846424E (el) |
SI (1) | SI1846424T1 (el) |
TW (1) | TWI367886B (el) |
WO (1) | WO2006086600A1 (el) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090286791A1 (en) * | 2001-11-27 | 2009-11-19 | Takeda Pharmaceutical Company Limited | Amide Compounds |
WO2007011760A2 (en) * | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
HUE034863T2 (en) | 2005-11-09 | 2018-03-28 | Onyx Therapeutics Inc | Compound for inhibiting enzyme |
NZ603303A (en) | 2006-06-19 | 2014-05-30 | Onyx Therapeutics Inc | Peptide epoxyketones for proteasome inhibition |
CN105837608B (zh) * | 2007-08-06 | 2018-06-08 | 米伦纽姆医药公司 | 蛋白酶体抑制剂及其组合物和用途 |
WO2009026579A1 (en) * | 2007-08-23 | 2009-02-26 | Cornell Research Foundation, Inc. | Proteasome inhibitors and their use in treating pathogen infection and cancer |
WO2009045497A1 (en) | 2007-10-04 | 2009-04-09 | Proteolix, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
JP5600595B2 (ja) * | 2007-10-16 | 2014-10-01 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | プロテアソーム阻害剤 |
EP2088205A1 (en) | 2008-02-11 | 2009-08-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | PSMB10: A diagnosis marker and therapeutic target of chronic rejection. |
PT2730581T (pt) | 2008-06-17 | 2016-08-17 | Millennium Pharm Inc | Compostos de ésteres de boronato e suas composições farmacêuticas |
BRPI0916576A2 (pt) * | 2008-08-04 | 2017-06-27 | Chdi Inc | pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio. |
AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
EA035100B1 (ru) | 2008-10-21 | 2020-04-28 | Оникс Терапьютикс, Инк. | Комбинированная терапия с применением пептид эпоксикетонов |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
EP2238973A1 (en) | 2009-04-07 | 2010-10-13 | Cephalon France | Lyophilized preparations of proteasome inhibitors |
WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
AU2010341530B2 (en) | 2009-12-22 | 2016-03-10 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
WO2011091153A1 (en) | 2010-01-25 | 2011-07-28 | Chdi, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
CA2791651C (en) * | 2010-03-01 | 2019-08-20 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
US9126997B1 (en) | 2010-09-07 | 2015-09-08 | Northwestern University | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma |
WO2012048745A1 (en) * | 2010-10-14 | 2012-04-19 | Synthon Bv | Process for making bortezomib and intermediates for the process |
EP3243515B1 (en) | 2011-08-30 | 2019-10-16 | CHDI Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
WO2013033068A1 (en) | 2011-08-30 | 2013-03-07 | Stephen Martin Courtney | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
UY34897A (es) | 2012-07-09 | 2014-01-31 | Onyx Therapeutics Inc | Profarmacos de inhibidores peptidicos de expoxi cetona proteasa |
WO2014072985A1 (en) * | 2012-11-06 | 2014-05-15 | Natco Pharma Limited | Novel boronic acid derivatives as anti cancer agents |
US9493439B1 (en) | 2014-04-07 | 2016-11-15 | University Of Kentucky Research Foundation | Proteasome inhibitors |
JP7082861B6 (ja) * | 2014-04-08 | 2023-12-22 | アブリバ エービー | 新規な細胞透過性サクシネート化合物 |
US20150335668A1 (en) | 2014-05-20 | 2015-11-26 | Millennium Pharmaceuticals, Inc. | Method for cancer therapy |
EP3169684B1 (en) | 2014-07-17 | 2019-06-26 | CHDI Foundation, Inc. | Combination of kmo inhibitor 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid with antiviral agent for treating hiv related neurological disorders |
WO2018157820A1 (zh) | 2017-02-28 | 2018-09-07 | 正大天晴药业集团股份有限公司 | 氮杂环丁烷衍生物 |
GB201808149D0 (en) | 2018-05-18 | 2018-07-11 | Univ Court Univ Of Glasgow | Protected amino acids |
JP7434273B2 (ja) | 2018-08-02 | 2024-02-20 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | アゼチジン誘導体のボレート |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3301354A1 (de) | 1983-01-18 | 1984-07-19 | Matth. Hohner Ag, 7218 Trossingen | Elektronisches musikinstrument |
US4537773A (en) * | 1983-12-05 | 1985-08-27 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid derivatives |
US4499082A (en) * | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
US5242904A (en) * | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US5250720A (en) * | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
US5187157A (en) * | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
EP0315574A3 (de) * | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
AU3418389A (en) | 1988-03-28 | 1989-10-16 | Regents Of The University Of California, The | Nerve growth factor peptides |
US5023236A (en) * | 1988-04-07 | 1991-06-11 | Corvas, Inc. | Factor VII/VIIA active site inhibitors |
US5106948A (en) * | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
US5159060A (en) * | 1988-05-27 | 1992-10-27 | Mayo Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
US4963655A (en) * | 1988-05-27 | 1990-10-16 | Mayo Foundation For Medical Education And Research | Boron analogs of amino acid/peptide protease inhibitors |
DE3827340A1 (de) | 1988-08-12 | 1990-02-15 | Hoechst Ag | Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen |
JPH05506777A (ja) | 1990-03-05 | 1993-10-07 | セファロン、インコーポレーテッド | キモトリプシン様プロテアーゼ及びそれらの阻害剤 |
ATE149563T1 (de) | 1992-08-14 | 1997-03-15 | Procter & Gamble | Alpha-aminoborsäurehaltige flüssige waschmittel |
JPH08507754A (ja) | 1993-02-10 | 1996-08-20 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | Mhc−1拘束性抗原提示におけるatp−ユビキチン依存蛋白分解の役割およびそのインヒビター |
IL109319A0 (en) | 1993-04-27 | 1994-07-31 | Du Pont Merck Pharma | Amidino and guanidino substituted boronic acid compounds |
US5658885A (en) * | 1993-04-27 | 1997-08-19 | The Dupont Merck Pharmaceutical Company | Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes |
ATE227581T1 (de) | 1993-04-30 | 2002-11-15 | Merck & Co Inc | Thrombin-inhibitoren |
US5672582A (en) | 1993-04-30 | 1997-09-30 | Merck & Co., Inc. | Thrombin inhibitors |
FR2707085B1 (fr) * | 1993-06-30 | 1995-08-18 | Adir | Nouveaux dérivés d'alpha amino acides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
KR100316865B1 (ko) | 1993-10-01 | 2002-11-29 | 메렐 파마슈티칼스 인크. | 베타-아밀로이드단백질생성억제제 |
IL111175A0 (en) | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
GB9401483D0 (en) | 1994-01-26 | 1994-03-23 | Sandoz Ltd | Organic compounds |
US5693617A (en) * | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5614649A (en) * | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
US5550262A (en) * | 1994-11-14 | 1996-08-27 | Cephalon, Inc. | Multicatalytic protease inhibitors |
US5834487A (en) * | 1996-09-24 | 1998-11-10 | Cv Therapeutics | Inhibition of 26S and 20S proteasome by indanones |
CZ298749B6 (cs) | 1996-10-18 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
US6096778A (en) * | 1997-10-07 | 2000-08-01 | Cephalon, Inc. | α-ketoamide multicatalytic protease inhibitors |
EP1037626A1 (en) * | 1997-12-16 | 2000-09-27 | Cephalon, Inc. | Multicatalytic protease inhibitors for use as anti-tumor agents |
US6075150A (en) * | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
EP0995757A3 (en) | 1998-08-26 | 2002-05-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bivalent inhibitors of the proteasome |
NZ511197A (en) | 1998-10-20 | 2003-08-29 | Millenium Pharmaceuticals Inc | Method for monitoring proteasome inhibitor drug action |
EP1053750A1 (en) | 1999-04-22 | 2000-11-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis) |
AU4555800A (en) | 1999-04-27 | 2000-11-10 | Novartis Ag | Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors |
SE9901573D0 (sv) | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
EP1196436A2 (en) | 1999-07-07 | 2002-04-17 | Bristol-Myers Squibb Pharma Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
WO2001020995A1 (en) | 1999-09-23 | 2001-03-29 | Washington University | Compounds directed against pilus biogenesis and activity in pathogenic bacteria; methods and compositions for synthesis thereof |
EP1477180A1 (en) | 1999-10-20 | 2004-11-17 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone and hair growth |
MXPA03000626A (es) | 2000-07-21 | 2004-07-30 | Schering Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c. |
PT1326632E (pt) | 2000-10-12 | 2007-01-31 | Viromics Gmbh | Tratamento para o tratamento de infecções por vírus da hepatite |
DK2251344T3 (en) | 2001-01-25 | 2016-05-09 | Us Of America Represented By The Secretary Dept Of Health And Human Services | Formulation of boronic acid |
JP2004534526A (ja) | 2001-04-09 | 2004-11-18 | ショー、アラン、クリスチァン | 細胞内細菌からのタンパク質を同定する方法 |
US7214769B2 (en) | 2001-05-23 | 2007-05-08 | The Curators Of The University Of Missouri | Method for inverse solid phase synthesis of peptides |
DE60209227T2 (de) | 2001-05-30 | 2006-08-17 | Novartis Ag | 2-((n-(2-amino-3-(heteroaryl- oder -aryl)propionyl)aminoacyl)amino)-alkylboronsäurederivate |
KR100399359B1 (ko) * | 2001-07-07 | 2003-09-26 | 삼성전자주식회사 | 전하 펌프 회로 |
AU2002324734A1 (en) | 2001-08-16 | 2003-03-03 | Levente Fabry-Asztalos | Borinic acid protease inhibitors |
WO2003033507A1 (fr) | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant |
JP4412586B2 (ja) * | 2002-01-08 | 2010-02-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | エポネマイシンおよびエポキソマイシン類似物およびそれらの用途 |
JP4101840B2 (ja) | 2003-08-13 | 2008-06-18 | セイコープレシジョン株式会社 | カードの製造方法及びカード製造装置 |
US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
UA97536C2 (en) | 2007-08-06 | 2012-02-27 | Милленниум Фармасьютикалз, Инк. | Proteasome inhibitors |
-
2006
- 2006-02-09 US US11/351,193 patent/US7468383B2/en not_active Expired - Fee Related
- 2006-02-10 EP EP06734698A patent/EP1846424B1/en not_active Not-in-force
- 2006-02-10 AU AU2006213814A patent/AU2006213814B2/en not_active Ceased
- 2006-02-10 NZ NZ560607A patent/NZ560607A/en not_active IP Right Cessation
- 2006-02-10 CA CA2597273A patent/CA2597273C/en not_active Expired - Fee Related
- 2006-02-10 TW TW095104473A patent/TWI367886B/zh not_active IP Right Cessation
- 2006-02-10 ES ES06734698T patent/ES2339698T3/es active Active
- 2006-02-10 AT AT06734698T patent/ATE456571T1/de active
- 2006-02-10 DE DE602006012013T patent/DE602006012013D1/de active Active
- 2006-02-10 PL PL06734698T patent/PL1846424T3/pl unknown
- 2006-02-10 MX MX2007009664A patent/MX2007009664A/es active IP Right Grant
- 2006-02-10 MY MYPI20060567A patent/MY147921A/en unknown
- 2006-02-10 WO PCT/US2006/004664 patent/WO2006086600A1/en active Application Filing
- 2006-02-10 DK DK06734698.1T patent/DK1846424T3/da active
- 2006-02-10 PT PT06734698T patent/PT1846424E/pt unknown
- 2006-02-10 JP JP2007555228A patent/JP2008530108A/ja active Pending
- 2006-02-10 SI SI200630615T patent/SI1846424T1/sl unknown
-
2007
- 2007-07-17 IL IL184678A patent/IL184678A/en not_active IP Right Cessation
- 2007-11-09 HK HK07112239.9A patent/HK1106534A1/xx not_active IP Right Cessation
-
2008
- 2008-11-06 US US12/265,998 patent/US8283367B2/en not_active Expired - Fee Related
-
2010
- 2010-04-27 CY CY20101100375T patent/CY1109985T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
HK1106534A1 (en) | 2008-03-14 |
JP2008530108A (ja) | 2008-08-07 |
ES2339698T3 (es) | 2010-05-24 |
TWI367886B (en) | 2012-07-11 |
IL184678A0 (en) | 2007-12-03 |
TW200640936A (en) | 2006-12-01 |
US20060189806A1 (en) | 2006-08-24 |
MY147921A (en) | 2013-02-15 |
EP1846424A1 (en) | 2007-10-24 |
WO2006086600A1 (en) | 2006-08-17 |
IL184678A (en) | 2012-05-31 |
DK1846424T3 (da) | 2010-05-17 |
NZ560607A (en) | 2009-11-27 |
DE602006012013D1 (de) | 2010-03-18 |
PL1846424T3 (pl) | 2010-06-30 |
CA2597273A1 (en) | 2006-08-17 |
CA2597273C (en) | 2013-12-17 |
AU2006213814A1 (en) | 2006-08-17 |
MX2007009664A (es) | 2007-09-26 |
SI1846424T1 (sl) | 2010-05-31 |
AU2006213814B2 (en) | 2011-10-13 |
ATE456571T1 (de) | 2010-02-15 |
PT1846424E (pt) | 2010-04-15 |
US8283367B2 (en) | 2012-10-09 |
US7468383B2 (en) | 2008-12-23 |
US20090075936A1 (en) | 2009-03-19 |
EP1846424B1 (en) | 2010-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109985T1 (el) | Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων | |
CY1109551T1 (el) | Πρωτεασωμικοι αναστολεις και μεθοδοι χρησιμοποιησης αυτων | |
ATE423087T1 (de) | Proteasome inhibitoren und deren verwendung | |
NL301145I2 (nl) | Tirbanibulin | |
CY1117678T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
EA201290894A1 (ru) | Азетидиновые производные пиперидин-4-ила как ингибиторы jak1 | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
DE602006018057D1 (de) | Substituierte chinolone und verwendungsverfahren | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA200970737A1 (ru) | Оксабициклогептаны и оксабициклогептены, их получение и применение | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
MY162518A (en) | Proteasome inhibitors and methods of using the same | |
EA200701815A1 (ru) | 6-гетероарил-1,2,3,4,4а,10в-гексагидрофенантридины в качестве pde-4 ингибиторов для лечения воспалительных заболеваний | |
UA110108C2 (xx) | Азетидинові похідні піперидин-4-ілу як інгібітори jak1 | |
EA201890558A1 (ru) | Азетидиновые производные пиперидин-4-ила как ингибиторы jak1 |